Arbutus Biopharma
ABUS
144 hedge funds and large institutions have $389M invested in Arbutus Biopharma in 2024 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 12 closing their positions.
329% more call options, than puts
Call options by funds: $9.3M | Put options by funds: $2.17M
133% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 12
47% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 32
30% more capital invested
Capital invested by funds: $298M → $389M (+$90.8M)
10% more funds holding
Funds holding: 131 → 144 (+13)
2.3% more ownership
Funds ownership: 51.25% → 53.55% (+2.3%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.27M |
| 2 |
State Street
Boston,
Massachusetts
|
+$5.65M |
| 3 |
Charles Schwab
San Francisco,
California
|
+$3.19M |
| 4 |
Morgan Stanley
New York
|
+$2.87M |
| 5 |
BlackRock
New York
|
+$2.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$4.6M |
| 2 |
Citigroup
New York
|
-$3.96M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.51M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.77M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$991K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
HSBC Holdings
London,
United Kingdom
| – | -$40.9K | -13,449 | Closed |
|
|
KAS
152
Kestra Advisory Services
Austin,
Texas
| – | -$33.4K | -10,800 | Closed |
|
|
C
153
Covestor
London,
United Kingdom
| – | -$21K | -6,700 | Closed |
|
|
FIA
154
FNY Investment Advisers
New York
| – | -$11K | -3,800 | Closed |
|
|
CTC
155
Central Trust Company
Jefferson City,
Missouri
| – | -$309 | -100 | Closed |
|
|
OWA
156
Opal Wealth Advisors
Jericho,
New York
| – | -$309 | -100 | Closed |
|
ABUS Hedge Fund Activity: Q3 2024 in Review
144 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2024, worth a combined $389M — up 30% from $298M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ABUS positions and 12 closed out — a net gain of 16 holders — while 47 added to existing stakes and 32 trimmed.
The largest buyer was Vanguard Group, adding an estimated $7.27M. The largest seller was ADAR1 Capital Management, cutting an estimated $4.6M.
- 144 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2024, up from 131 in Q2 2024.
- Funds reported $389M of Arbutus Biopharma stock for Q3 2024, up 30% quarter-over-quarter.
- 28 funds opened new Arbutus Biopharma positions in Q3 2024 and 12 closed out, a net change of +16 holders.
- The largest Arbutus Biopharma buyer in Q3 2024 was Vanguard Group, an estimated $7.27M added.
- The largest Arbutus Biopharma seller in Q3 2024 was ADAR1 Capital Management, an estimated $4.6M sold.
Based on aggregated 13F filings for Q3 2024.